Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Research Tools > Antibodies

Categories

[Search within category]

Rapid Structure-guided Generation of Antibodies for Detecting Protein Phosphorylation Modifications

This invention is a rapid, robust method to generate high-quality, renewable antibodies specific to protein phosphorylations via antibody scaffolds.

Methods And Reagents For Live Biopsy

This invention identifies a set of antibodies that allow direct imaging of immune cells in a tumor biospecimen.

Novel ELISA assay to detect SULF2 in patient samples

This ELISA technique detects Sulfatase2 (SULF2), an extracellular heparan sulfate-degrading enzyme that is overexpressed in many cancers. Furthermore, this technique can potentially serve as a diagnostic for cirrhosis.

Method of Producing Highly Specific Antibodies to Extracellular Proteins

This invention enables the direct selection of membrane proteins in their native state, thereby facilitating the production of highly specific antibodies.

Novel Biomarkers for Autoimmune-mediated Lung Disease

Interstitial lung disease (ILD) is a common manifestation of systemic autoimmune diseases such as rheumatoid arthritis (RA), lupus and scleroderma, which can lead to inflammation and scarring of the lung and, consequently, to hypoxemia, pulmonary hypertension and death.  It is estimated that ILD occurs in approximately 15 percent of patients with RA.  Very little is known about how ILD disorders arise and what role loss of immune tolerance plays in ILD development.  Presently, there are no validated lung-specific autoantigens for diagnosis of autoimmune-mediated lung disease.  Current options for ILD treatment are limited to powerful immunosuppressive medications with significant side effects.  Identification of novel pulmonary biomarkers is sorely needed to develop better diagnostic methods and therapies for ILD.

Diagnostic Antibodies for In Vivo Visualization of Tumor Cells

Molecular imaging of cancer has the potential to facilitate early detection and to provide a more detailed assessment of disease and tumor margin.  Molecular imaging probes have been heralded by the FDA Critical Path Initiative as tools to increase the speed and cost-effectiveness of clinical trials for cancer therapies.  However, imaging probes currently in use in the clinic are limited by a lack of specificity and/or sensitivity or are limited to a small subset of cancers.  Therefore, new molecular imaging probes with more broad applications to cancer are needed.

  • Go to Page: